S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ICU · SeaStar Medical Holding Corporation
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
SeaStar Medical Holding Corp (ICU)
NASDAQ NMS - GLOBAL MARKET
Health Care
$3.17
+0.14
(+4.62%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.17
$3.06
$3.17
52-WEEK RANGE
$3.17
$2.07
$6.50
What's happening
- ICU is up 4.62% today, trading at $3.17. — Live quote
- Volume today (5,207) is well below its 3-month average of 112,380. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.91 actual vs. $-0.98 estimated (+7.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 1
Buy 3
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (5 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ICU
+27.08%
vs S&P 500
+14.31%
1-YEAR RETURN
ICU
-51.51%
vs S&P 500
-66.07%
6-MONTH RETURN
ICU
-26.68%
3-MONTH RETURN
ICU
-20.98%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.91
Est. $-0.98
BEAT +7.1%
2026-04-26 (Q1 2026)
$-0.90
Est. $-0.83
MISS -8.0%
2026-01-26 (Q4 2025)
$-0.80
Est. $-1.07
BEAT +25.3%
2025-10-26 (Q3 2025)
$-1.30
Est. $-1.51
BEAT +14.2%
Valuation Measures & Ratios
Enterprise Value4$6.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)7.85
Price / Book73.41
EV4 / Revenue3.86
EV4 / EBITDA—
Profit Margin-795.50%
Operating Margin-816.64%
Return on Equity (ROE8)-162.75%
Return on Assets (ROA9)-109.90%
Avg Volume (3M)112,380
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | — | — | $4.66B | $14.19B |
| P/E | — | — | — | -345.84 | -586.69 |
| Price/Sales | — | — | — | 6673.33 | 39301.56 |
| Price/Book | — | — | — | 1396.19 | 25111.26 |
| EV/Revenue | — | — | — | 6673.33 | 39301.56 |
| ROE | — | — | — | -403.71% | -4280.18% |
| ROA | — | — | — | -160.90% | -170.30% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short143,724
Change from Prior Settlement+18.11%
% of Float—
Days to Cover (Short Ratio)3.16
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 82.0% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-05; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -795.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -51.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ICU
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $615.0K | $495.0K | $183.0K | $338.0K | $293.0K | $68.0K | $0 | $0 |
| Gross profit | $561.0K | $449.0K | $169.0K | $311.0K | $293.0K | $68.0K | $0 | $0 |
| Operating income | -$3.8M | -$3.6M | -$3.6M | -$1.8M | -$3.8M | -$4.5M | -$4.7M | -$4.0M |
| Net income | -$3.7M | -$3.5M | -$3.5M | -$2.0M | -$3.8M | -$4.5M | -$3.2M | -$12.7M |
| EPS (diluted) | — | — | — | $-0.18 | $-0.44 | $-1.10 | $-1.03 | $-4.73 |
| EPS (basic) | $-0.91 | $-0.90 | $-0.13 | $-1.77 | $-4.38 | $-1.10 | $-1.03 | $-4.73 |
| Operating margin | -$616 | -$728 | -$2.0K | -$520 | -$1.3K | -$6.6K | — | — |
| Net margin | -$607 | -$711 | -$1.9K | -$592 | -$1.3K | -$6.6K | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $8.6M | $11.3M | $14.2M | $15.5M | $8.4M | $14.2M | $4.7M | $4.6M |
| Total liabilities | $4.4M | $3.9M | $3.7M | $4.1M | $5.0M | $7.0M | $6.8M | $6.6M |
| Stockholders' equity | $4.3M | $7.3M | $10.4M | $11.5M | $3.3M | $565.0K | -$2.2M | -$2.1K |
| Total current assets | $8.2M | $10.8M | $13.6M | $14.9M | $7.6M | $6.8M | $3.8M | $3.6M |
| Total current liabilities | $4.4M | $3.9M | $3.7M | $4.1M | $5.0M | $7.0M | $6.8M | $6.6M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | $208.0K | $179.0K | $237.0K | $221.0K | $217.0K | $110.0K | $112.0K | $68.0K |
| Inventory | $77.0K | $57.0K | $66.0K | $83.0K | $77.0K | $44.0K | $0 | $0 |
| Other non-current assets | $421.0K | $499.0K | $578.0K | $656.0K | — | — | $892.0K | — |
| Accounts payable | $750.0K | $719.0K | $948.0K | $2.0M | $3.2M | $3.4M | $3.0M | $3.7M |
| Accrued liabilities | $3.5M | $2.9M | $2.3M | $2.0M | $1.9M | $3.3M | $3.2M | $2.3M |
| Deferred revenue (current) | — | — | — | — | — | — | $0 | $550.0K |
| Short-term debt | — | — | — | — | — | — | $574.0K | — |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Common stock & paid-in capital | $4.0K | $4.0K | $4.0K | $3.0K | $2.0K | $2.0K | $2.0K | $1.0K |
| Retained earnings | -$159.0M | -$155.2M | -$151.7M | -$148.8M | -$145.3M | -$143.3M | -$139.6M | -$135.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.0M | -$2.8M | -$4.1M | -$3.8M | -$3.0M | -$2.7M | -$4.7M | -$5.0M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | $605.0K | $129.0K | $2.3M | $11.3M | $4.0M | $6.1M | $4.4M | $5.9M |
| Share-based compensation | -$99.0K | $91.0K | $70.0K | $290.0K | $97.0K | $167.0K | $212.0K | $200.0K |
| Change in accounts receivable | $29.0K | -$58.0K | $16.0K | $4.0K | $107.0K | -$2.0K | $44.0K | $68.0K |
| Change in inventory | $20.0K | -$9.0K | -$17.0K | $6.0K | $33.0K | $44.0K | $0 | $0 |
| Change in accounts payable | $31.0K | -$229.0K | -$1.1M | -$1.1M | -$239.0K | $351.0K | -$423.0K | -$603.0K |
| Debt issued | — | — | — | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $135.0K | $0 | — | — |
| Gross profit | $1.2M | $135.0K | $0 | — | — |
| Operating income | -$12.2M | -$17.8M | -$14.2M | -$11.6M | -$4.4M |
| Net income | -$12.2M | -$24.8M | -$26.2M | -$12.2M | -$4.6M |
| EPS (diluted) | — | $-6.63 | $-30.26 | $-1.48 | $-0.63 |
| EPS (basic) | $-5.86 | $-66.33 | $-30.26 | $-1.48 | $-0.63 |
| Operating margin | -$987 | -$13.2K | — | — | — |
| Net margin | -$985 | -$18.4K | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|
| Total assets | $14.2M | $4.7M | $3.5M | $2.5M | $2.6M |
| Total liabilities | $3.7M | $6.8M | $17.4M | $18.5M | $14.4M |
| Stockholders' equity | $10.4M | -$2.2M | -$13.9M | -$16.0M | -$11.8M |
| Total current assets | $13.6M | $3.8M | $2.3M | $1.2M | $1.2M |
| Total current liabilities | $3.7M | $6.8M | $13.0M | $12.8M | $14.4M |
| Cash & equivalents | — | — | — | — | — |
| Accounts receivable | $237.0K | $112.0K | $0 | — | — |
| Inventory | $66.0K | $0 | — | — | — |
| Other non-current assets | $578.0K | $892.0K | — | — | — |
| Accounts payable | $948.0K | $3.0M | $4.4M | $5.0M | $4.4M |
| Accrued liabilities | $2.3M | $3.2M | $1.5M | $1.7M | $1.4M |
| Deferred revenue (current) | — | $0 | $100.0K | — | — |
| Short-term debt | — | $574.0K | $565.0K | — | — |
| Long-term debt | — | — | $4.1M | — | — |
| Common stock & paid-in capital | $4.0K | $2.0K | $1.0K | $3.0K | $2.0K |
| Retained earnings | -$151.7M | -$139.6M | -$114.7M | -$105.3M | -$98.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$13.6M | -$16.0M | -$10.3M | -$7.8M | -$5.1M |
| Investing cash flow | — | — | — | — | -$105.6M |
| Financing cash flow | $23.8M | $17.6M | $10.4M | $7.3M | $2.8M |
| Share-based compensation | $624.0K | $887.0K | $1.9M | $1.3M | — |
| Change in accounts receivable | $125.0K | $112.0K | $0 | — | — |
| Change in inventory | $66.0K | $0 | — | $0 | -$55.0K |
| Change in accounts payable | -$2.1M | -$1.3M | $2.4M | $1.5M | -$297.0K |
| Debt issued | — | $1.1M | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ICU as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-04 to 2026-08-18
Recent transactions
- Insiders have net bought 750 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Messinger Michael (Chief Financial Officer) — Open market purchase of 750 shares on 2026-08-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)750 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+750
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Messinger Michael | Chief Financial Officer | Open market purchase | 2026-08-18 | 750 |
| Schlorff Eric | Chief Executive Officer | Grant / award | 2026-07-01 | 10,288 |
| Chung Kevin | Chief Medical Officer | Grant / award | 2026-07-01 | 7,202 |
| Vincent Bernadette N | Director | Grant / award | 2026-07-01 | 4,000 |
| Neuman John | Director | Grant / award | 2026-07-01 | 4,000 |
| Van Heel Kenneth | Director | Grant / award | 2026-07-01 | 4,000 |
| Baird Jennifer A | Director | Grant / award | 2026-07-01 | 4,000 |
| Towne Bradford K | Principal Accounting Officer | Grant / award | 2026-02-06 | 7,500 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Messinger Michael | Chief Financial Officer | Open market purchase | 750 | $3.27 |
| 2026-07-01 | Schlorff Eric | Chief Executive Officer | Grant / award | 10,288 | $0.00 |
| 2026-07-01 | Chung Kevin | Chief Medical Officer | Grant / award | 7,202 | $0.00 |
| 2026-07-01 | Vincent Bernadette N | Director | Grant / award | 4,000 | $0.00 |
| 2026-07-01 | Neuman John | Director | Grant / award | 4,000 | $0.00 |
| 2026-07-01 | Van Heel Kenneth | Director | Grant / award | 4,000 | $0.00 |
| 2026-07-01 | Baird Jennifer A | Director | Grant / award | 4,000 | $0.00 |
| 2026-02-06 | Van Heel Kenneth | Director | Grant / award | 3,000 | $0.00 |
| 2026-02-06 | Neuman John | Director | Grant / award | 3,000 | $0.00 |
| 2026-02-06 | Vincent Bernadette N | Director | Grant / award | 3,000 | $0.00 |
| 2026-02-06 | Baird Jennifer A | Director | Grant / award | 3,000 | $0.00 |
| 2026-02-06 | Towne Bradford K | Principal Accounting Officer | Grant / award | 7,500 | $0.00 |
| 2026-02-06 | Chung Kevin | Chief Medical Officer | Grant / award | 15,000 | $0.00 |
| 2026-02-06 | Schlorff Eric | Chief Executive Officer | Grant / award | 30,000 | $0.00 |
| 2025-12-19 | Baird Jennifer A | Director | Open market purchase | 4,200 | $0.24 |
| 2025-12-09 | Messinger Michael | Chief Financial Officer | Open market purchase | 14,500 | $0.35 |
| 2025-08-27 | Van Heel Kenneth | Reporting person | Open market purchase | 10,000 | $0.86 |
| 2025-08-26 | Van Heel Kenneth | Reporting person | Open market purchase | 25,000 | $0.89 |
| 2025-08-22 | Chung Kevin | Chief Medical Officer | Open market purchase | 10,000 | $0.80 |
| 2025-07-10 | Baird Jennifer A | Reporting person | Grant / award | 4,000 | $0.00 |
| 2025-07-10 | Neuman John | Reporting person | Grant / award | 4,000 | $0.00 |
| 2025-07-10 | Vincent Bernadette N | Reporting person | Grant / award | 4,000 | $0.00 |
| 2025-07-10 | Van Heel Kenneth | Reporting person | Grant / award | 4,000 | $0.00 |
| 2025-07-01 | Chung Kevin | Chief Medical Officer | Option exercise | 5,000 | $0.00 |
| 2025-07-01 | Schlorff Eric | Chief Executive Officer | Option exercise | 21,667 | $0.00 |
| 2025-06-30 | Baird Jennifer A | Reporting person | Open market purchase | 10,000 | $0.42 |
| 2025-06-04 | Neuman John | Reporting person | Option exercise | 2,667 | $0.00 |
| 2025-06-04 | Vincent Bernadette N | Reporting person | Option exercise | 2,667 | $0.00 |
| 2025-06-04 | Van Heel Kenneth | Reporting person | Option exercise | 4,000 | $0.00 |
| 2025-06-04 | Baird Jennifer A | Reporting person | Option exercise | 2,667 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:17 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-05 | 8-K | 2026-10-05 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-06-17 | 8-K | 2026-06-17 | View on SEC.gov → |
Recent news
Headlines about ICU (SeaStar Medical Holding Corporation). Links open the publisher — we don’t host full articles.
-
'It's all e-accidents now': as injuries surge, one family shares their ICU ordeal
Newcastle Herald · 2026-10-21 -
ICUGS Shares Enter Call Auction as Borsa Istanbul Triggers Circuit Breaker
The Globe and Mail · 2026-10-21 -
Argus raises target for ICU Medical stock to USD 171.00
AD HOC NEWS · 2026-10-20 -
PTV. . #PTVNewsTonight | Team PH wins junior coed advanced title at ICU Asian Championships
Facebook · 2026-10-20 -
Multidisciplinary Rounds Catch Overlooked ICU Devices: Pooja Roy, MD
AJMC · 2026-10-19 -
Delayed Access to Care Drives Late-Stage ICU Cases: Adan Mora, MD
AJMC · 2026-10-19 -
ICU Medical, Inc. (ICUI) Stock forecasts
Yahoo Finance UK · 2026-10-18 -
ICU Medical stock faces an 18.29 percent gap to USD 192.80 target
AD HOC NEWS · 2026-10-17
No headlines in this category right now — try “All”.